| Literature DB >> 28991212 |
Susan Costantini1, Eliana Guerriero2, Roberta Teta3, Francesca Capone4, Alessia Caso5, Angela Sorice6, Giovanna Romano7, Adrianna Ianora8, Nadia Ruocco9,10,11, Alfredo Budillon12, Valeria Costantino13, Maria Costantini14.
Abstract
Marine sponges are an excellent source of bioactive secondary metabolites for pharmacological applications. In the present study, we evaluated the chemistry, cytotoxicity and metabolomics of an organic extract from the Mediterranean marine sponge Geodia cydonium, collected in coastal waters of the Gulf of Naples. We identified an active fraction able to block proliferation of breast cancer cell lines MCF-7, MDA-MB231, and MDA-MB468 and to induce cellular apoptosis, whereas it was inactive on normal breast cells (MCF-10A). Metabolomic studies showed that this active fraction was able to interfere with amino acid metabolism, as well as to modulate glycolysis and glycosphingolipid metabolic pathways. In addition, the evaluation of the cytokinome profile on the polar fractions of three treated breast cancer cell lines (compared to untreated cells) demonstrated that this fraction induced a slight anti-inflammatory effect. Finally, the chemical entities present in this fraction were analyzed by liquid chromatography high resolution mass spectrometry combined with molecular networking.Entities:
Keywords: breast cancer; cytokines; cytotoxicity; metabolomics; sponges
Mesh:
Substances:
Year: 2017 PMID: 28991212 PMCID: PMC5666794 DOI: 10.3390/ijms18102112
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Cell proliferation. Cell viability rate (CR) related to breast cancer cells: (a) MCF-7; (b) MDA-MB231; and (c) MDA-MB468, after treatment with the active sponge Geodia cydonium sub-fraction for 24 (blue line) and 48 (red line) h.
Figure 2(Left) Two-dimensional molecular network of the active fraction from the sponge Geodia cydonium. In the clusters indicated with (a–f), nodes are labeled with parent m/z ratio (M+H)+ ions; edge thickness is related to cosine similarity score; (Right) Liquid chromatography-high resolution mass spectrometry (LC-HRMS) profile of the active fraction; the most abundant ions are represented by colored bold contour squares.
Apoptosis. Percentage of live, apoptotic and dead cells expressed as mean ± standard deviation by the Muse Annexin V and Dead Cell assay in MCF-7, MDA-MB231 and MDA-MB468 cells after treatment with IC50 concentrations obtained after 48 h. Untreated cells were used as control.
| Cells | Live (%) | Apoptosis (%) | Dead (%) |
|---|---|---|---|
| MCF-7 untreated | 94.8 ± 2.4 | 3.8 ± 2.6 | 1.4 ± 0.8 |
| MCF-7 treated | 47.8 ± 1.8 | 51.2 ± 1.1 | 0.9 ± 0.4 |
| MDA-MB231 untreated | 97.7 ± 3.2 | 2.1 ± 2.3 | 0 |
| MDA-MB231 treated | 36.4 ± 3.9 | 63.1 ± 2.5 | 0 |
| MDA-MB468 untreated | 96.3 ± 2.4 | 3.5 ± 2.3 | 0.30 ± 0.05 |
| MDA-MB468 treated | 38.7 ± 3.2 | 56.6 ± 3.1 | 3.9 ± 0.9 |
Primer sequences of the genes used in this study.
| Gene Name | Primer Sequence (5′→3′) |
|---|---|
| GCC CAA GCC CTT GCA CAT (18) | |
| TGG TGG CAC AAA GCT GAT GAC (21) | |
| CTG GCC CCT GTC ATC TTC TG (20) | |
| CCG TCA TGT GCT GTG ACT GC (20) | |
| GGA CGA ACT GGA CAG TAA CAT GG (23) | |
| GCA AAG TAG AAA AGG GCG ACA AC (23) | |
| CAGTGGAGGCCGACTTCTTG (20) | |
| TGGCACAAAGCGACTGGAT (19) | |
| GGATGGCCACTGTGAATAACTG (22) | |
| TCGAGGACATCGCTCTCTCA (20) | |
| TCT GGC ACC ACA CCT TCT ACA ATG (24) | |
| AGC ACA GCC TGG ATA GCA ACG (21) |
Figure 3RT-qPCR analysis: mRNA fold changes were evaluated as ratios between the expression levels of five genes in three breast cancer cell lines, MCF-7, MDA-MB231 and MDA-MB468, after treatment with the active fraction compared to untreated cells.
Cell percentages in the cell cycle phases (gap 0 (G0), gap1 (G1), synthesis (S), gap2 (G2) and mitosis (M) phases) expressed as mean ± standard deviation by the Muse Cell cycle assay in MCF-7, MDA-MB231 and MDA-MB468 cells after treatment with IC50 concentrations obtained after 48 h. Untreated cells were used as control.
| Cells | G0/G1 | S | M |
|---|---|---|---|
| MCF7 untreated | 51.7 ± 2.3 | 17.3 ± 2.7 | 30.7 ± 1.7 |
| MCF7 treated | 45.3 ± 2.1 | 14.2 ± 3.4 | 31.2 ± 2.3 |
| MDAMB231 untreated | 59.1 ± 3.2 | 16.9 ± 3.9 | 21.8 ± 2.4 |
| MDAMB231 treated | 63.7 ± 1.4 | 15.2 ± 4.3 | 18.8 ± 2.3 |
| MDAMB468 untreated | 47.1 ± 3.9 | 16.9 ± 4.5 | 33.7 ± 1.8 |
| MDAMB468 treated | 39.2 ± 4.9 | 14.2 ± 2.9 | 39.1 ± 2.2 |
List of 1H chemical shift (ppm) of metabolites found in three breast cancer cells.
| Metabolites | Group | Chemical Shift | Metabolites | Group | Chemical Shift |
|---|---|---|---|---|---|
| Lipids | C18H3 | 0.6–0.68 | α-Glucose | C4H | 3.42 |
| Lipids | C26H3 | 0.87–0.89 | β-Glucose | C5H | 3.47 |
| Leucine | δCH3 | 0.96 | β-Glucose | C3H | 3.48 |
| Valine | γCH3 | 0.97 | α-Glucose | C2H | 3.54 |
| Valine | βCH3 | 1.04 | Glycine | CH2 | 3.56 |
| Threonine | γCH3 | 1.20 | Phosphocholine | NCH2 | 3.6 |
| Isoleucine | γCH2u | 1.24 | Valine | αCH | 3.63 |
| Threonine | γCH3 | 1.32 | Glycero-phosphocholine | NCH2 | 3.68 |
| Lactate | βCH3 | 1.34 | α-Glucose | C3H | 3.72 |
| Isoleucine | γCH2u | 1.46 | Alanine | αCH | 3.75 |
| Alanine | βCH3 | 1.48 | Glutamine | αCH | 3.76 |
| Lipids | COCH2CH2 | 1.59–1.61 | Glutamate | αCH | 3.77 |
| Leucine | βCH2 | 1.72 | α-Glucose | C6H | 3.78 |
| Lysine | δCH2 | 1.72 | α-Glucose | C5H | 3.84 |
| Lysine | βCH2 | 1.90 | β-Glucose | C6H | 3.90 |
| Arginine | βCH2 | 1.91 | Phenylalanine | αCH | 4.02 |
| Glutamate | βCH | 2.04 | Choline | αCH2 | 4.07 |
| Proline | βCH2 | 2.06 | Lactate | αCH | 4.11 |
| Glutathione | βCH2 | 2.14 | Proline | αCH | 4.12 |
| Glutamine | βCH2 | 2.15 | Phosphocholine | OCH2 | 4.16 |
| Valine | βCH | 2.28 | Threonine | βCH | 4.26 |
| Glutamate | γCH2 | 2.34 | Glycero-phosphocholine | OCH2 | 4.32 |
| Proline | βCH2d | 2.35 | β-Glucose | C1H | 5.2 |
| Glutamine | γCH2 | 2.43 | α-Glucose | C1H | 5.24 |
| Aspartate | β′CH2 | 2.79 | Histidine | C4H | 6.91 |
| Lysine | εCH2 | 3.03 | Histidine | C4H′ | 6.99 |
| Phosphocholine | N(CH3)3 | 3.18 | Tyrosine | C2,6H | 7.15–7.2 |
| Choline | N(CH3)3 | 3.19 | Tyrosine | C2,6H′ | 7.18 |
| Arginine | δCH2 | 3.22 | Phenylalanine | C4H | 7.33 |
| Glycero-phosphocholine | N(CH3)3 | 3.22 | Phenylalanine | C2,6H | 7.39 |
| β-Glucose | C2H | 3.26 | Phenylalanine | C3,5H | 7.43 |
| Proline | CH2u | 3.34 | Histidine | C2H | 7.78 |
Figure 4Orthogonal Projections to Latent Structures discriminant analysis (OPLS-DA) plots: (A) OPLS-DA and variable importance in projection (VIP) analysis where the metabolites increased or decreased in the endo-metabolome of: (B) MCF-7; (C) MDA-MB231; and (D) MDA-MB468 cells after treatment with the active fraction from the sponge Geodia cydonium, compared to untreated cells.
Figure 5Cytokine levels in breast cancer cells. Scheme reporting the cytokines modulated by the active fraction obtained from the sponge Geodia cydonium. In particular, anti-inflammatory cytokines that are increased after treatment are reported in red and pro-inflammatory and pro-angiogenic cytokines that are decreased after treatment are reported in green. Blank cells indicate that the cytokines are not modulated by active fraction.